Table 3. Factors affecting acceptability of undergoing RRESDO among premenopausal women who have not undergone RRSO.
| OR | SE | P > |z| | 95% CI | |
|---|---|---|---|---|
| Prior knowledge of tubal origin of OC | 1.725 | 0.376 | 0.147 | 0.833-3.655 |
| Personal history of BC | 1.184 | 0.558 | 0.761 | 0.404-3.672 |
| Previous RRM | 0.647 | 0.407 | 0.285 | 0.286-1.421 |
| Family complete | 1.146 | 0.516 | 0.792 | 0.417-3.214 |
| Carrier status | 1.788 | 0.911 | 0.523 | 0.273-10.928 |
| Marital status | 0.679 | 0.425 | 0.362 | 0.289-1.545 |
| Ethnicity | 0.492 | 0.599 | 0.237 | 0.153-1.66 |
| Education | 0.876 | 0.408 | 0.747 | 0.388-1.94 |
| Income | 1.053 | 0.177 | 0.77 | 0.742-1.492 |
| Timing of future OC prevention surgery | 0.286 | 1.171 | 0.286 | 0.014-2.095 |
| Family history | ||||
| BC | 2.889 | 0.63 | 0.093 | 0.813-9.999 |
| OC | 1.019 | 0.785 | 0.98 | 0.214-4.799 |
| BC and OC | 0.869 | 0.867 | 0.871 | 0.158-4.835 |
| Concerns over premature menopause sequelae influencing decision to undergo RRESDO | ||||
| Hot flushes/night sweats | 1.27 | 0.502 | 0.634 | 0.475-3.451 |
| Looking older | 0.804 | 0.5 | 0.663 | 0.295-2.131 |
| Decreased libido/other sexual side effects | 2.918 | 0.477 | 0.025 | 1.163-7.648 |
| Loss of fertility | 1.568 | 0.608 | 0.459 | 0.468-5.208 |
| Osteoporosis | 1.931 | 0.567 | 0.246 | 0.628-5.895 |
| Heart disease | 0.845 | 0.625 | 0.787 | 0.239-2.832 |
| Dementia/memory dysfunction | 2.435 | 0.67 | 0.184 | 0.67-9.495 |
| Impact on survival | 0.488 | 0.511 | 0.16 | 0.17-1.281 |
| Acceptability of having to take HRT until 51 years | 1.501 | 0.437 | 0.353 | 0.64-3.586 |
| Potential benefits of RRESDO influencing decision to undergo RRESDO | ||||
| Reduces risk of OC without premature menopause | 9.007 | 1.195 | 0.066 | 1.149-192.856 |
| Inspection of tubes/ovaries by doctor | 2.323 | 0.798 | 0.291 | 0.474-11.476 |
| delays hot flushes, night sweats | 5.028 | 0.719 | 0.025 | 1.218-21.172 |
| delays osteoporosis | 1.08 | 1.332 | 0.954 | 0.083-17.385 |
| delays potential change to sexual function | 2.945 | 0.735 | 0.142 | 0.682-12.753 |
| Not associated with increased risk of heart disease | 1.279 | 1.127 | 0.827 | 0.114-11.238 |
| Potential limitations of RRESDO influencing decision to undergo RRESDO | ||||
| Two staged surgery | 444.078 | 1.672 | <0.001 | *28.04-22814.9 |
| Potential premature menopause | 1.939 | 0.888 | 0.456 | 0.348-12.145 |
| Increased complication rate | 0.78 | 1.014 | 0.807 | 0.091-5.333 |
| Interval monitoring between surgeries | 59.027 | 1.471 | 0.006 | 4.221-1548.671* |
| Additional time in hospital | 0.028 | 1.94 | 0.065 | 0-1.081 |
| Additional time off work for surgery/post-operative recovery | 6.166 | 1.453 | 0.21 | 0.406-139.284 |
| Precise level of OC risk reduction with ES unknown | 14.556 | 1.095 | 0.015 | 1.961-160.637 |
| Developing an interval OC between the two surgeries | 9.554 | 1.05 | 0.032 | 1.405-93.72 |
BC, breast cancer; FH, family history; HRT, hormone replacement therapy; OC, ovarian cancer; RRESDO, risk-reducing early salpingectomy with delayed oophorectomy; RRM, risk-reducing mastectomy.
Multiple logistic regression analysis on factors affecting acceptability of undergoing RRESDO (‘yes’ versus ‘no’ responses) in 198 premenopausal women who have not undergone RRSO. Model adjusted for marital status, ethnicity, education, income, family history of ovarian cancer/breast cancer, risk-reducing mastectomy and personal history of breast cancer.
Prior knowledge of tubal origin of OC: ‘yes’ versus ‘no’; personal history of BC: ‘yes’ versus ‘no’; previous RRM: ‘yes’ versus ‘no’; family complete: ‘no’ versus ‘yes’; carrier status: BRCA1/BRCA2 versus intermediate risk (RAD51C carrier/RAD51D carrier/BRIP1 carrier/BRCA negative but strong FH of OC/BRCA untested but strong FH of OC); marital status: in a relationship (married, cohabiting/living with partner) versus not in a relationship (single, divorced, separated, widowed); ethnicity: non-caucasian versus caucasian; education: university level education (PhD, Masters, Bachelor’s degree) versus below university level education (NVQ4, A-level/NVQ3, NVQ1/NVQ2, GCSE/O-level/CSE, no formal qualification); timing of future OC prevention surgery: planning surgery now/within 5 years versus not planning surgery; FH BC (FH of BC alone plus FH of BC and OC): ‘yes’ versus ‘no’; FH OC (FH of OC alone plus FH of OC and BC): ‘yes’ versus ‘no’; FH BC and OC: ‘yes’ versus ‘no’; hot flushes/night sweats: ‘yes’ versus ‘no’; looking older: ‘yes’ versus ‘no’; decreased libido/other sexual side effects: ‘yes’ versus ‘no’; loss of fertility: ‘yes’ versus ‘no’; osteoporosis (self-reported): ‘yes’ versus ‘no’; heart disease: ‘yes’ versus ‘no’; dementia/memory dysfunction: ‘yes’ versus ‘no’; impact on survival: ‘yes’ versus ‘no’; acceptability of having to take HRT until 51 years: ‘yes’ versus ‘no’; reduces risk of OC without premature menopause: ‘yes’ versus ‘no’; inspection of tubes/ovaries by doctor: ‘yes’ versus ‘no’; delays hot flushes/night sweats: ‘yes’ versus ‘no’; delays osteoporosis: ‘yes’ versus ‘no’; delays potential change to sexual function: ‘yes’ versus ‘no’; not associated with increased risk of heart disease: ‘yes’ versus ‘no’; two-stage surgery: ‘yes’ versus ‘no’; potential premature menopause: ‘yes’ versus ‘no’; increased complication rate: ‘yes’ versus ‘no’; interval monitoring between surgeries: ‘yes’ versus ‘no’; additional time in hospital: ‘yes’ versus ‘no’; additional time off work for surgery/postoperative recovery: ‘yes’ versus ‘no’; precise level of OC risk reduction with ES unknown: ‘yes’ versus ‘no’; developing an interval OC between the two surgeries: ‘yes’ versus ‘no’.
Extreme value of some upper limits of confidence intervals indicate that there were too few responses in some categories of responses.